These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 11279608)

  • 1. Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants.
    Gimm O; Dziema H; Brown J; de la Puente A; Hoang-Vu C; Dralle H; Plass C; Eng C
    Int J Cancer; 2001 Apr; 92(1):70-4. PubMed ID: 11279608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma.
    Gimm O; Greco A; Hoang-Vu C; Dralle H; Pierotti MA; Eng C
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2784-7. PubMed ID: 10443680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-representation of a germline variant in the gene encoding RET co-receptor GFRalpha-1 but not GFRalpha-2 or GFRalpha-3 in cases with sporadic medullary thyroid carcinoma.
    Gimm O; Dziema H; Brown J; Hoang-Vu C; Hinze R; Dralle H; Mulligan LM; Eng C
    Oncogene; 2001 Apr; 20(17):2161-70. PubMed ID: 11360200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
    Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression.
    McGregor LM; McCune BK; Graff JR; McDowell PR; Romans KE; Yancopoulos GD; Ball DW; Baylin SB; Nelkin BD
    Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4540-5. PubMed ID: 10200298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
    Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
    Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ret proto-oncogene in the WAG/Rij rat strain: an animal model for inherited C-cell carcinoma?
    De Miguel M; Fernández-Santos JM; Trigo-Sánchez I; Matera I; Ceccherini I; Martín I; Romeo G; Galera-Davidson H
    Lab Anim; 2003 Jul; 37(3):215-21. PubMed ID: 12869284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
    Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F
    Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
    Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary thyroid carcinoma in a child with a new RET mutation and a RET polymorphism.
    Vandenbosch K; Renard M; Uyttebroeck A; Sciot R; Matthijs G; Legius E
    Genet Couns; 2005; 16(1):95-100. PubMed ID: 15844786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
    Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
    Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
    Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
    Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.